[Pharmacotherapy in the treatment of obesity].MMW Fortschr Med. 2006 Mar 02; 148(9):36-8.MF
Abstract
Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity. Used in combination with increased exercise and dietary measures, both are capable of significantly reducing weight. In the USA and Europe, official approval for the selective cannabinoid receptor antagonist, rimonabant has been applied for.
MeSH
Pub Type(s)
Journal Article
Review
Language
ger
PubMed ID
16566392
Citation
Hamann, Andreas. "[Pharmacotherapy in the Treatment of Obesity]." MMW Fortschritte Der Medizin, vol. 148, no. 9, 2006, pp. 36-8.
Hamann A. [Pharmacotherapy in the treatment of obesity]. MMW Fortschr Med. 2006;148(9):36-8.
Hamann, A. (2006). [Pharmacotherapy in the treatment of obesity]. MMW Fortschritte Der Medizin, 148(9), 36-8.
Hamann A. [Pharmacotherapy in the Treatment of Obesity]. MMW Fortschr Med. 2006 Mar 2;148(9):36-8. PubMed PMID: 16566392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - [Pharmacotherapy in the treatment of obesity].
A1 - Hamann,Andreas,
PY - 2006/3/29/pubmed
PY - 2006/5/6/medline
PY - 2006/3/29/entrez
SP - 36
EP - 8
JF - MMW Fortschritte der Medizin
JO - MMW Fortschr Med
VL - 148
IS - 9
N2 - Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity. Used in combination with increased exercise and dietary measures, both are capable of significantly reducing weight. In the USA and Europe, official approval for the selective cannabinoid receptor antagonist, rimonabant has been applied for.
SN - 1438-3276
UR - https://www.unboundmedicine.com/medline/citation/16566392/[Pharmacotherapy_in_the_treatment_of_obesity]_
L2 - http://www.diseaseinfosearch.org/result/9028
DB - PRIME
DP - Unbound Medicine
ER -